ライフサイエンスコーパス: active surveillance

1 and in 127 asymptomatic persons in Thailand (active surveillance).

2 Utilization of active surveillance.

3 elopment of an adverse drug reaction through active surveillance.

4 using MRI in the routine follow-up of men on active surveillance.

5 ance biopsies, and may enhance acceptance of active surveillance.

6 s infection in the ICU, without the need for active surveillance.

7 Error rates were measured through active surveillance.

8 y, especially among men who are eligible for active surveillance.

9 and adverse events were ascertained through active surveillance.

10 This was a prospective, population-based, active surveillance.

11 those with low-risk cancer on or considering active surveillance.

12 potentially aggressive tumors unsuitable for active surveillance.

13 grade disease feel more comfortable choosing active surveillance.

14 eview will examine the role of MRI in men on active surveillance.

15 sk prostate cancer and had chosen to undergo active surveillance.

16 tion to their role in promoting adherence to active surveillance.

17 of alphavirus infection were detected during active surveillance.

18 fixed power of 150 mW/cm for 22 min 15 s) or active surveillance.

19 implications for targeted vector control and active surveillance.

20 d patients with prostate cancer selected for active surveillance.

21 Cases were identified by passive followed by active surveillance.

22 cancers who are being encouraged to consider active surveillance.

23 The primary outcome was selection of active surveillance.

24 s of non-high-grade DCIS that would preclude active surveillance.

25 nt driving factor for physicians to practice active surveillance.

26 asses (SRMs) include excision, ablation, and active surveillance.

27 SSI was assessed using postdischarge active surveillance.

28 ere significantly associated with pursuit of active surveillance.

29 or by greater than 0.4-0.5 cm/year while on active surveillance.

30 ing growth rate of solid renal masses during active surveillance.

31 comes data mature, to ablative therapies and active surveillance.

32 accurate, and few deaths were missed through active surveillance.

33 each intensive care unit, in addition to the active surveillance.

34 tatectomy, 598 (23.5%) EBRT, and 429 (16.8%) active surveillance.

35 an upgrade in Gleason score while undergoing active surveillance.

36 riod comprising 15.2 million person-years of active surveillance.

37 omes of men with prostate cancer enrolled in active surveillance.

38 n the decision whether to treat or to pursue active surveillance.

39 al surveillance biopsy for monitoring men on active surveillance.

40 rnal beam radiotherapy, and brachytherapy vs active surveillance.

41 ted photodynamic therapy and 207 patients to active surveillance.

42 monitored via prospective, population-based active surveillance.

43 ient management, particularly with regard to active surveillance.

44 xternal beam radiotherapy, brachytherapy, or active surveillance.

45 external beam radiation therapy (EBRT), and active surveillance.

46 diarrhea and systematically enrolled through active surveillance.

47 on 3 + 4 = 7) prostate cancer may be offered active surveillance.

48 of these patients could benefit from initial active surveillance.

49 s with metastatic renal-cell carcinoma under active surveillance.

50 T (-18.0 points; 95% CI, -20.5 to -15.4) and active surveillance (-12.7 points; 95% CI, -16.0 to -9.3

51 Of 1141 enrolled men, 314 pursued active surveillance (27.5%), 469 radical prostatectomy (

52 with better urinary irritative symptoms than active surveillance (5.2 points; 95% CI, 3.2 to 7.2).

53 5% CI, 18.7%-19.5%]) and watchful waiting or active surveillance (9.6% [95% CI, 9.3%-9.9%]).

54 , or radical prostatectomy or followed up by active surveillance (a strategy of close monitoring of n

55 At the time of randomization to active surveillance, a significant proportion of patient

56 s, as shown even in recent studies promoting active surveillance; a low recurrence rate of 1-5%; and

57 and urinary incontinence than either EBRT or active surveillance after 3 years and was associated wit

58 In a prospective, population-based, active surveillance, all OM episodes submitted for middl

59 , and the men in the control group underwent active surveillance alone.

60 RO colonization, and infection by leveraging active surveillance and antibiotic treatment data for 23

61 s bacteremia in the ICU without the need for active surveillance and decontamination.

62 with the 1976 swine influenza vaccine, both active surveillance and end-of-season analyses on chart-

63 ontrolled (i.e., case-crossover) designs for active surveillance and evaluate the ability of the case

64 Active surveillance and focal therapy have become hot to

65 cer plays a substantial role in adherence to active surveillance and outcomes of men with the disease

66 r is emerging as a management option between active surveillance and radical treatments.

67 d drug-related adverse events and encourages active surveillance and reporting by all physicians.

68 er million) were bacterially contaminated by active surveillance and resulted in 5 STRs occurring 9 t

69 vances have influenced patient selection for active surveillance and review the range of different in

70 cal malaria episodes were detected by weekly active surveillance and self-referral.

71 To determine TRALI incidence by prospective, active surveillance and to identify risk factors by a ca

72 he most appropriate eligibility criteria for active surveillance and what triggers for intervention s

73 atients who had prostate cancer managed with active surveillance and who had undergone both MR imagin

74 prostate cancer , 61.5% (eight of 13) under active surveillance, and 72.0% (18 of 25) in whom recurr

75 y is the highest expenditure associated with active surveillance, and increasing the frequency of pro

76 with PCa prostate cancer who were undergoing active surveillance, and men with treated PCa prostate c

77 statectomy, 12% choosing watchful waiting or active surveillance, and only 3% undergoing radiotherapy

78 invasive cancer, evaluation of a strategy of active surveillance, and testing of decision-making tool

79 two prevalent responses among men undergoing active surveillance; anxiety and uncertainty.

80 Active surveillance appears to reduce prostate cancer he

81 ly works for applying urinary biomarkers for active surveillance are underway.

82 the literature on psychosocial responses to active surveillance as well as educational and support s

83 Active surveillance (AS) and watchful waiting (WW) have

84 ients with prostate cancer (PCa) for initial active surveillance (AS) has been questioned on the basi

85 Active surveillance (AS) is a treatment option for men w

86 Active surveillance (AS) is increasingly accepted for ma

87 Active surveillance (AS), per the National Comprehensive

88 y, or radical prostatectomy) or observation (active surveillance [AS] or watchful waiting [WW]).

89 It is also of use in following up men on active surveillance, as a way to detect change in tumour

90 FoodNet conducts active surveillance at 10 US sites for laboratory-confir

91 Compared with active surveillance at 3 months, worsened urinary incont

92 r case-control observational study involving active surveillance at 6 US pediatric medical institutio

93 with intussusception were identified through active surveillance at 69 hospitals (16 in Mexico and 53

94 ere compared between each treatment group vs active surveillance at each time point.

95 Best practice for active surveillance at the time of study design was foll

96 given year and at least 12% of men remain on active surveillance at year 5.

97 Active surveillance became as effective as WW in men age

98 We mimicked active surveillance by conducting sequential analyses af

99 dysfunction often precedes symptoms, needing active surveillance by echocardiography to determine the

100 tments that viruses gain access to are under active surveillance by one or more pattern recognition r

101 Recent reports have suggested active surveillance can be a cost-effective approach and

102 Multiple studies suggest that MRI early in active surveillance can identify men whose prostate canc

103 Compared with immediate treatment, active surveillance can result in a net per-patient savi

104 ); advanced infection control practices (ie, active surveillance, chlorhexidine bathing, decolonizati

105 immediate treatment and updates of multiple active surveillance cohorts for men with early-stage pro

106 In reported active surveillance cohorts, prostate cancer death and m

107 cs of managing low-risk prostate cancer with active surveillance compared with other standard therapi

108 on-resistant prostate cancer and those under active surveillance comprised LPD3 (15 of 31 castration-

109 Active surveillance continues to remain a highly valued

110 In the absence of routine, active surveillance, coupled with the common failure to

111 sistant S. aureus colonization documented by active surveillance culture before the development of ve

112 e predictive value, suggesting that negative active surveillance culture can accurately exclude methi

113 Active surveillance culture for extended-spectrum beta-l

114 e performance characteristics of once weekly active surveillance culture of methicillin-resistant S.

115 s colonization as ascertained by once-weekly active surveillance culture yielded high specificity and

116 acteriaceae digestive colonization by weekly active surveillance cultures could reliably exclude the

117 with glycerol, thus broadening the scope of active surveillance cultures for both clinical and resea

118 als are under increasing pressure to perform active surveillance cultures for methicillin-resistant S

119 ntroduction of chikungunya in 2015, by using active surveillance data to correct reported dengue case

120 Combining active surveillance data with routine dengue reports imp

121 Using active surveillance data, we evaluated geographic and te

122 andomizing women with non-high-grade DCIS to active surveillance, defined as imaging surveillance wit

123 Active surveillance demonstrated the considerable burden

124 Active surveillance demonstrates lower 5-year costs over

125 W: The long-term safety and effectiveness of active surveillance depends on our ability to select app

126 Physician reimbursement for active surveillance exceeded that from upfront radical p

127 to whole gland radiation or surgery or when active surveillance 'fails' (the patient transitions fro

128 admissions specific to rotavirus captured by active surveillance fell by 61-70%.

129 retrospective series of patients undergoing active surveillance for 957 SRMs indicates that the majo

130 Active surveillance for bloodstream infections has been

131 he Global Polio Laboratory Network maintains active surveillance for circulating live polioviruses by

132 n in a previously CRE-free region, including active surveillance for CRE carriers and enhanced isolat

133 Active surveillance for CSI testis cancer leads to excel

134 We conducted weekly, active surveillance for diarrhea in 19 villages in Ecuad

135 d serve as a benchmark to compare the use of active surveillance for favorable-risk disease around th

136 Active surveillance for favorable-risk prostate cancer i

137 Active surveillance for ILI was conducted for approximat

138 infection, detected through population-based active surveillance for influenza in Bangladesh, to asse

139 Active surveillance for influenza-like illness (ILI) was

140 Active surveillance for influenza-like illnesses continu

141 Use of active surveillance for intermediate-risk disease remain

142 We conducted active surveillance for laboratory-confirmed cases of no

143 ts passive surveillance and FoodNet conducts active surveillance for laboratory-confirmed Vibrio infe

144 tive Surveillance Network (FoodNet) conducts active surveillance for laboratory-confirmed Y. enteroco

145 nationwide, population-based study on use of active surveillance for localized prostate cancer in Swe

146 screening and biopsy; increasing reliance on active surveillance for low-risk cancer; restricting rad

147 Changes include active surveillance for low-risk lesions and a watchful

148 l therapy was developed as an alternative to active surveillance for men with low-risk disease and a

149 ive treatment and use of watchful waiting or active surveillance for men with prostate cancer.

150 he start of a bundled intervention including active surveillance for MRSA.

151 This was prospective national active surveillance for neonatal HSV disease through the

152 ntion's Emerging Infections Program conducts active surveillance for persons hospitalized with labora

153 Active surveillance for posttreatment adverse events was

154 We performed active surveillance for rotavirus hospitalizations at th

155 ne Surveillance Network (NVSN) has conducted active surveillance for RVA at pediatric hospitals and e

156 Active surveillance for TDR is needed to guide ART usage

157 determined that the recommendations from the Active Surveillance for the Management of Localized Pros

158 ASCO endorsed the Active Surveillance for the Management of Localized Pros

159 The Active Surveillance for the Management of Localized Pros

160 warranted to investigate the feasibility of active surveillance for the management of low-grade DCIS

161 ate cancer, and focal therapy may complement active surveillance for those men wishing to continue a

162 ed 4 follow-up examinations (2011-2013) with active surveillance for vital status and hospitalization

163 group compared with 120 (58%) of 207 in the active surveillance group (adjusted hazard ratio 0.34, 9

164 treatment compared with 28 (14%) men in the active surveillance group (adjusted risk ratio 3.67, 95%

165 The most common serious adverse event in the active surveillance group was myocardial infarction (thr

166 otodynamic therapy group vs one [<1%] in the active surveillance group), acute urinary retention (thr

167 32) in the no prior PCa prostate cancer and active surveillance groups.

168 Active surveillance has become the dominant management f

169 The safety of active surveillance has been reinforced by recent report

170 Active surveillance has emerged as an alternative to imm

171 Single studies with relevance to active surveillance have evaluated microRNAs, circulatin

172 virus epidemiology by use of data from eight active surveillance hospitals.

173 with fewer urinary irritative symptoms than active surveillance; however, no meaningful differences

174 ren aged 2-59 months were identified through active surveillance in 13 sites.

175 68% (351 of 518) with low-risk disease chose active surveillance in 2014.

176 We implemented active surveillance in 297 households in Peru from Octob

177 al treatments as long as fewer than 70% exit active surveillance in any given year and at least 12% o

178 f this review is to analyze the economics of active surveillance in comparison with other therapies.

179 re is associated with increased selection of active surveillance in men with low-risk prostate cancer

180 Crude rates of selection of active surveillance in patients seen at a multidisciplin

181 RECENT FINDINGS: Evaluating the economics of active surveillance in patients with low-risk prostate c

182 inary clinic is associated with selection of active surveillance in patients with low-risk prostate c

183 he measurement of the true economic value of active surveillance in the future.

184 ed biopsy approaches for early diagnosis and active surveillance, in addition to focal therapy.

185 ed this treatment with the standard of care, active surveillance, in men with low-risk prostate cance

186 h for small renal masses that have undergone active surveillance (including biopsy-proven cancers) an

187 lemental support services for men undergoing active surveillance, including support groups and Intern

188 The use of active surveillance increased in men of all ages from 57

189 The investigation included active surveillance, interviews, examinations of ill and

190 Furthermore, decisions regarding active surveillance involve closely monitoring growth ki

191 Active surveillance is a management strategy for early-s

192 Active surveillance is a reasonable initial strategy in

193 Active surveillance is a well tolerated treatment option

194 Active surveillance is an alternative to initial treatme

195 Active surveillance is an important option to reduce pro

196 Active surveillance is appropriate for most men with low

197 Active surveillance is associated with more quality-adju

198 PURPOSE OF REVIEW: Active surveillance is gaining wider acceptance in the u

199 m the United States show that greater use of active surveillance is important for prostate cancer scr

200 Active surveillance is increasingly accepted as a treatm

201 Continued active surveillance is needed to monitor RVA genotypes i

202 that includes antimicrobial stewardship and active surveillance is needed to prevent CRE infections

203 Active surveillance is now considered a viable treatment

204 ason score </= 6) localized prostate cancer, active surveillance is the recommended disease managemen

205 The aim of active surveillance is to avoid radical treatment and it

206 ms of overtreating low-risk prostate cancer, active surveillance may help settle the controversy surr

207 Compared with active surveillance, mean sexual dysfunction scores wors

208 recruited from July 2009 to April 2013 using active surveillance methodology.

209 Community-based mapping and active surveillance must accompany the implementation of

210 e of linked data from the Foodborne Diseases Active Surveillance Network (FoodNet) and National Antim

211 The Foodborne Diseases Active Surveillance Network (FoodNet) conducts active su

212 The Foodborne Diseases Active Surveillance Network (FoodNet) conducts populatio

213 The Foodborne Diseases Active Surveillance Network (FoodNet) conducts surveilla

214 We analyzed Foodborne Diseases Active Surveillance Network (FoodNet) data for patients

215 data from the most recent Foodborne Diseases Active Surveillance Network (FoodNet) Population Survey

216 urveys to physicians in 8 Foodborne Diseases Active Surveillance Network (FoodNet) sites to assess th

217 n during 1996-2009 in the Foodborne Diseases Active Surveillance Network (FoodNet), an active, popula

218 Using data from the Foodborne Diseases Active Surveillance Network (FoodNet), we describe trave

219 during 1997-2009 via the Foodborne Diseases Active Surveillance Network (FoodNet), which gradually e

220 ) system and the 10-state Foodborne Diseases Active Surveillance Network (FoodNet).

221 ites participating in the Foodborne Diseases Active Surveillance Network (FoodNet).

222 t or food vehicle) in the Foodborne Diseases Active Surveillance Network (FoodNet).

223 g 2004-2009 data from the Foodborne Diseases Active Surveillance Network (FoodNet).

224 of deaths reported to the Foodborne Diseases Active Surveillance Network (FoodNet).

225 By using data from the US Foodborne Diseases Active Surveillance Network and other sources, we estima

226 athogens monitored by the Foodborne Diseases Active Surveillance Network for which >50% of illnesses

227 Using a multicenter, active surveillance network from 2 rotavirus seasons (20

228 Monitoring (PRISM) system is a cohort-based active surveillance network initiated by the US Departme

229 An active surveillance network was set up to analyze the im

230 Monitoring System and the Foodborne Diseases Active Surveillance Network.

231 ce Monitoring System, and Foodborne Diseases Active Surveillance Network.

232 A strategy of prospective, active surveillance of a clinical registry rapidly ident

233 We evaluated a strategy of prospective, active surveillance of a national clinical registry to m

234 dy the spread of the 2 viruses, we conducted active surveillance of acute febrile syndromes throughou

235 Population- and laboratory-based active surveillance of CRE conducted among individuals l

236 When selecting patients for active surveillance of DCIS, factors other than tumor bi

237 We used data from active surveillance of diarrheal disease prevalence gath

238 (via examinations, annual phone interviews, active surveillance of discharges from local hospitals,

239 Studies have shown that active surveillance of high-risk patients for VRE coloni

240 We conducted population-based, prospective, active surveillance of iGAS infections throughout the st

241 Staphylococcus aureus (MRSA) prevalence via active surveillance of inpatient populations.

242 (i.e., using within-person comparisons) for active surveillance of newly marketed drugs.

243 onors and offer prophylaxis to and undertake active surveillance of recipients.

244 ions for radical surgery, focal therapy, and active surveillance on a 'per-lesion' strategy.

245 timal therapy if it will benefit them and/or active surveillance or best supportive care if it will n

246 d by physicians, mostly neurologists, during active surveillance or identified in the provincial hosp

247 nfavorable tumor pathology in the setting of active surveillance, or in clinical contexts that are in

248 Active surveillance--or close monitoring of PSA levels c

249 cer showed that the estimated direct cost of active surveillance over long term was the lowest compar

250 Increasing interest in active surveillance, particularly for tumors of limited

251 er, three of four studies come from the same active surveillance patient cohort.

252 Active surveillance patients were enrolled.

253 Europe and the United States have championed active surveillance per the "search and destroy" model.

254 epeat prostate biopsy strategies, as well as active surveillance, potentially improving sampling effi

255 Registry established in 1969 coupled with an active surveillance program of screening persons with ch

256 ate cancer prior to commencement of a formal active surveillance programme.

257 Active surveillance programs for MRSA utilize either mol

258 rmacovigilance systems, including conducting active surveillance projects.

259 , we report the long-term outcome of a large active surveillance protocol in men with favorable-risk

260 Active surveillance protocols should include prostate-sp

261 Watchful waiting or active surveillance, radiation therapy, or radical prost

262 In settings with active surveillance, reductions in OM caused by vaccine-

263 Active surveillance represents a cost-effective strategy

264 Active surveillance should be an initial management opti

265 Active surveillance should be considered in this group o

266 vior, leading to increased implementation of active surveillance strategies.

267 Consequently, the active surveillance strategy for low-risk prostate cance

268 ns Hopkins University (JHU); Canary Prostate Active Surveillance Study (PASS); University of Californ

269 ed on the results from a large, prospective, active-surveillance study of gastroenteritis outbreaks i

270 n clinical contexts that are informative for active surveillance, such as men with low-risk prostate

271 Active surveillance suggests patient risk 10- to 40-fold

272 The established active surveillance system at 2 hospitals in the capital

273 In this population- and laboratory-based active surveillance system in 7 states, the incidence of

274 Detailed considerations to an active surveillance system that includes reporting, iden

275 ay potentially play a key role in developing active surveillance, systematic evaluation of simple app

276 Recent data from passive and active surveillance systems in the United States indicat

277 phasizing the need for establishing regional active surveillance systems.

278 e studies (e.g., >25,000 patients) show that active surveillance testing (AST) followed by contact pr

279 Active surveillance testing to identify and isolate asym

280 oints for Enterobacteriaceae and the lack of active surveillance tests hamper the clinical laboratory

281 Active surveillance (the serial monitoring for disease p

282 Cases were identified using active surveillance through an established ophthalmic su

283 from January 1966 through January 2016, with active surveillance through December 2016.

284 The role of MRI in active surveillance to date has been in assessing men wi

285 ology and patient characteristics, and offer active surveillance to eligible men with low-risk tumors

286 eatment with radical prostatectomy, EBRT, or active surveillance was ascertained within 1 year of dia

287 Active surveillance was associated with the greatest QAL

288 ine in sexual domain scores between EBRT and active surveillance was not clinically significant (-4.3

289 pective, enhanced, national population-based active surveillance was undertaken to determine the inci

290 Active surveillance was underused, and a significant pro

291 isolation, patient and staff cohorting, and active surveillance were issued.

292 ths, mean scores between treatment groups vs active surveillance were not significantly different in

293 and method of relapse detection observed on active surveillance were recorded.

294 cancer were used as cases and patients under active surveillance were used as controls.

295 For carefully selected men, active surveillance with curative intent appears to be a

296 On the basis of these data, active surveillance with curative intent, in which activ

297 Active surveillance (with visits to health facilities) i

298 d studies comparing an early AVR strategy to active surveillance, with an emphasis on the level of ev

299 seminoma and 1,344 CSI seminoma managed with active surveillance, with the majority treated between 1

300 cal treatment plus ADT, and watchful waiting/active surveillance (WW/AS).